The clinical phase III programme commenced on zicronapine
* Based on the solid outcome from the clinical phase II studies, the clinical phase III programme has now been initiated * The first study is a risperidone-controlled fixed-dose study which will enrol ~160 patients with schizophrenia. Treatment duration is six months * Classical short term efficacy studies will be initiated in due time. H. Lundbeck A/S (Lundbeck) announced today the advancement of zicronapine intoclinical phase III based on the positive clinical phase II data. The first study in the clinical phase III programme is expected to enrol some160 patients with the